COMMUNIQUÉS West-GlobeNewswire

Affimed Introduces ROCK(TM) Platform for Tailored Immune Cell Engagers
03/05/2018
Redirected Optimized Cell Killing (ROCK TM ) Platform Engages NK and T Cells to Activate Innate and Adaptive Immunity Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical [...]
Affimed to Present at Deutsche Bank's 43rd Annual Health Care Conference
03/05/2018
Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess [...]
Orion Corporation: Managers' transactions - Timo Maasilta
03/05/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Timo Maasilta Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Ari Lehtoranta
03/05/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Ari Lehtoranta Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Mikael Silvennoinen
03/05/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST Orion Corporation: Managers' transactions - Mikael Silvennoinen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]
Orion Corporation: Managers' transactions - Heikki Westerlund
03/05/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST Orion Corporation: Managers' transactions - Heikki Westerlund Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]
Orion Corporation: Managers' transactions - Hilpi Rautelin
03/05/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Hilpi Rautelin Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Sirpa Jalkanen
03/05/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Sirpa Jalkanen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Eija Ronkainen
03/05/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST Orion Corporation: Managers' transactions - Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Interim Report, First Quarter 2018, BioPorto Group
03/05/2018
May 3, 2018 Announcement no. 10 Important milestones in global roll-out of The NGAL Test™ secured in first quarter 2018 In the first quarter of 2018, BioPorto secured multiple important milestones in the effort to [...]
CellaVision AB: Interim report January-March 2018
03/05/2018
Good profitability in a stable first quarter January 1-March 31, 2018 Net sales decreased by 17 % to SEK 77.6 million (93.1). Organic growth was -20 % (60). Operating profit was SEK 23.2 million (34.3). The operating [...]
Shire plc : Rule 2.9 Announcement
03/05/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 May 2018 Shire [...]
NICOX : Présentation de données scientifiques sur le NCX 667 au congrès ARVO 2018
03/05/2018
Communiqué de presse Nicox : Présentation de données scientifiques sur le NCX 667 au congrès ARVO 2018 NCX 667 démontre une réduction robuste de la pression intraoculaire, dose-dépendante, dans divers modèles oculaires [...]
Nicox announces the presentation of scientific data for NCX 667 at ARVO 2018
03/05/2018
Press Release Nicox announces the presentation of scientific data for NCX 667 at ARVO 2018 NCX 667 demonstrates robust, dose-dependent lowering of intraocular pressure in various normotensive and hypertensive ocular [...]
World Health Organization Grants Name ‘Seliforant’ to Sensorion’s SENS-111 Treatment
03/05/2018
Seliforant (formerly SENS-111) is a first-in-class histamine H4 receptor antagonist candidate selected for the treatment of vertigo of vestibular origin, in development to treat acute unilateral vestibulopathy (AUV), a [...]
Targovax ASA: First quarter 2018 results
03/05/2018
Oslo, Norway, 3 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2018 results. A meeting for [...]
IBA SA : IBA selected to install new proton therapy center in Italy
03/05/2018
IBA selected to install new proton therapy center in Italy Term sheet signed with the European Institute of Oncology (IEO) to install a Proteus ® ONE compact proton therapy solution in Milan Louvain-La-Neuve, Belgium, 3 [...]
IBA SA : IBA sélectionné pour l'installation d'un nouveau centre de protonthérapie en Italie
03/05/2018
IBA sélectionné pour l'installation d'un nouveau centre de protonthérapie en Italie Term sheet signée avec l'Institut Européen d'Oncologie (IEO) pour l'installation d'une solution compacte de protonthérapie Proteus ® [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
03/05/2018
REGULATED INFORMATION GHENT, Belgium, 3 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Pages